Health Care & Life Sciences » Pharmaceuticals | Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
24,179.00
52,631.00
37,758.50
46,247.50
35,384.60
14,145.60
Total Accounts Receivable
22,507.00
14,316.00
22,646.50
19,638.30
29,577.10
14,299.90
Inventories
311.00
240.00
1,733.60
1,705.80
611.40
1,054.40
Other Current Assets
391.00
881.00
5,618.90
2,369.60
1,903.20
1,824.70
Total Current Assets
47,388.00
68,068.00
67,757.50
69,961.20
67,476.40
31,324.60
Net Property, Plant & Equipment
24.00
26.00
397.30
1,059.40
333.30
942.40
Intangible Assets
1,582.00
1,709.00
72,547.10
23,578.30
6,765.90
40,750
Total Assets
55,550.00
76,689.00
152,309.30
103,804.00
79,098.70
76,055.90
ST Debt & Current Portion LT Debt
-
-
-
56.30
8,408.50
Accounts Payable
11,627.00
9,581.00
14,898.10
21,404.50
18,878.20
Other Current Liabilities
3,051.00
3,201.00
10,828.00
6,631.50
6,789.70
Total Current Liabilities
14,678.00
12,782.00
25,726.10
28,092.30
34,076.50
Long-Term Debt
-
-
48,032.30
48,920.20
14,440.20
Deferred Taxes
6,556.00
6,886.00
11,607.30
9,205.00
4,523.10
Other Liabilities
2,114.00
1,168.00
3,182.40
2,633.80
1,844.30
Total Liabilities
16,792.00
13,950.00
76,940.90
79,646.30
50,361.10
Common Equity (Total)
38,758.00
62,739.00
75,368.40
24,157.70
28,737.70
Total Shareholders' Equity
38,758.00
62,739.00
75,368.40
24,157.70
28,737.70
Total Equity
38,758.00
62,739.00
75,368.40
24,157.70
28,737.70
Liabilities & Shareholders' Equity
55,550.00
76,689.00
152,309.30
103,804.00
79,098.70

About Cipher Pharmaceuticals

View Profile
Address
209 Oak Park Boulevard
Oakville Ontario L6H 0M2
Canada
Employees -
Website http://www.cipherpharma.com
Updated 07/08/2019
Cipher Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the robust and diversified portfolio of commercial and late-stage products. It also acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly or through partners. Its products include Actikerall, Aclaro, Beteflam, Epuris, Vaniqa, Dermadexin, Pruridexin, Ozenoxacin, Lipofen, Conzip, and Durela.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.